ABSTRACT The recombinant human growth hormone (GH) has been used for the treatment of growth hormone deficiency (GHD) and diverse short stature state, and its physiological and therapeutic effects are well documented. However, since the effect of GH treatment on metabolic disorders has not been well characterized, we injected GH to Western diet-fed low-density lipoprotein receptor-deficient (Ldlr −/−) mice to understand the exact effect of GH on metabolic diseases including atherosclerosis, hepatic steatosis, and obesity. Exogenous GH treatment increased plasma IGF-1 concentration and decreased body weight without affecting serum lipid profiles. GH treatment changed neither atherosclerotic lesion size nor collagen and smooth muscle cells accumulation in the lesion. GH treatment reduced macrophage accumulation in adipose tissue. Importantly, GH treatment attenuated hepatic steatosis and inflammation. The hepatic expression IL-1β mRNA were decreased by GH treatment. The mRNA and protein levels of CD36 were markedly decreased in GH treated mice without significant changes in other molecules related to lipid metabolism. Therefore, the treatment of GH treatment could attenuate hepatic steatosis and inflammation with downregulation of CD36 expression in hyperlipidemic condition.

中文翻译：

---

生长激素治疗通过下调肝脏 CD36 表达减轻高脂血症小鼠的肝脏脂肪变性

摘要 重组人生长激素 (GH) 已被用于治疗生长激素缺乏症 (GHD) 和各种身材矮小状态，其生理和治疗效果已得到充分证明。然而，由于 GH 治疗对代谢紊乱的影响尚未得到很好的表征，我们将 GH 注射到西方饮食喂养的低密度脂蛋白受体缺陷 (Ldlr -/-) 小鼠中，以了解 GH 对代谢疾病的确切影响，包括动脉粥样硬化、肝脂肪变性和肥胖。外源性生长激素治疗增加血浆 IGF-1 浓度并降低体重，而不影响血清脂质谱。GH 治疗既不改变动脉粥样硬化病变的大小，也不改变病变中胶原蛋白和平滑肌细胞的积累。GH 治疗减少了脂肪组织中巨噬细胞的积累。重要的，GH 治疗减轻了肝脏脂肪变性和炎症。GH治疗降低肝脏表达IL-1β mRNA。CD36 的 mRNA 和蛋白质水平在 GH 治疗的小鼠中显着降低，而与脂质代谢相关的其他分子没有显着变化。因此，GH治疗可以通过下调高脂血症中CD36表达来减轻肝脏脂肪变性和炎症。